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The latest definition of intractable epilepsy by the International League Against 
Epilepsy (ILAE) provides clear inclusion criteria for this condition. It is estimated that 
about 20% of patients with epilepsy managed in a tertiary referral centre have 
intractable epilepsy. This study addresses the demographics, key markers, 
aetiologies, co-morbidities and therapeutic options associated with a group of 
patients who have epilepsy resistant to medication. Through greater understanding 
of our patient group, recommendations can be made to improve our approach to 
epilepsy through the clinical management, inclusive of the cost efficacy. This study 
aims to compare the differences of the centre‟s previously established concept of 
intractable epilepsy compared to the ILAE criteria. The study assesses how 
separating out this medication resistant group impacts on the long term care and 
enables earlier consideration of other interventions (e.g. Epilepsy surgery, vagal 
nerve stimulator and ketogenic diet). Early intervention with these alternative 
interventions may be more cost effective even for children managed in resource 
limited countries.   
 
Methodology 
Prospective identification was undertaken of intractability in children attending 
neurology and epilepsy clinics at Red Cross War Memorial Children‟s Hospital. A 
retrospective medical record review of the patients who met the ILAE definition of 
intractability was performed to obtain necessary demographic and clinical data.  
 
Results 
A total of 513 children were reviewed, 96 of whom met the inclusion criteria of 
intractable epilepsy (IE). This was 18.7% of the total group of children with epilepsy. 
Male to female ratio was 1.3:1 with a predominant mixed ancestry, followed by 
children of African descent. Ninety percent of the children with IE were from local 
urban regions. The median age was 7.9 years among children with IE. 57% of them 
had an epilepsy syndrome mainly Lennox-Gastaut syndrome (27.1%) followed by 
epilepsy with myoclonic atonic seizures (13.5%), West syndrome (12.5%), Dravet 
syndrome (2.1%) and Ohtahara syndrome (2.1%). Children with IE had a seizure 
age of onset median of 17months (mean 29 month, s.d. 30) and mean frequency of 
58 seizures per month (s.d. 180). The confirmation of the label IE took an average of 

















(excluding status epileptics) was found despite poly-pharmacy. Status epilepticus 
occurred in 82% of children with IE. Hypoxic ischemic encephalopathy (HIE) 
constituted 33% of all aetiologies followed by infections (20%) and structural brain 
malformations (16%). The median number of medications used in the intractable 
group was 4 and the median duration before considering failure of trial was 11 
months (mean15, s.d. 19). Other interventions were seldom used including ACTH, 
which was used in only 6% of IE patients, prednisone 10.4%, pyridoxine 6%, and 
IVIG 1%.  Only 2% of our cohort had vagal nerve stimulators and a similar 
percentage had epilepsy surgery. 54% of children with IE had neuroregression, 68% 
developmental delay, 16% had intellectual disabilities, 38% behavioural problems 
and another 8% had pervasive developmental disorders including autism. 
 
Conclusions and recommendations 
The latest definition of intractable epilepsy by the ILAE provided clear criteria to 
study the prevalence of IE among children with epilepsy. In comparison with local 
expert definitions IE was defined 4.1% more using ILAE definition. It took around 4.7 
years to recognize intractability in our centre. Several key markers were flagged in 
our study which could assist earlier identification of patients at risk of IE including 
seizure onset frequency, aetiology, epilepsy syndromes. Only a small percentage of 
our children had access to epilepsy surgery, ketogenic diet, and vagal nerve 
stimulator (VNS). Several disabilities especially developmental, intellectual, 
behavioural and social in addition to financial and eventually death are expected 
outcomes of children with intractable epilepsy. Early recognition can be achieved if 
awareness of the definition of intractability and its predictors is raised. Early referral 
to enable access to essential resources such as epilepsy surgery, would improve 


























Epilepsy is one of the most important childhood diseases. It is one of the most 
common chronic neurological disorders, affecting more than 50 million people 
worldwide (1). 
Epilepsy affects 3–5% of the population worldwide (2). It occurs in 1–2% of children, 
with the first 12 months of life carrying the highest incidence after which epilepsy 
plateaus until it decreases after 10 years of age (7, 8). More than 80 per 100 000 
people develop new-onset epilepsy every year, most commonly during childhood 
and in old age (3). Studies suggest that the lifetime and active prevalence of 
epilepsy were 7.3/1 000 and 6.7/1 000 respectively for children in South Africa (4). 
Worldwide estimates are recorded at 4 -10/1000 (1). Fortunately, most of the 
patients are treatable, with good outcome (5, 6). 
Because of un-standardized definitions as well as misdiagnoses, the incidence and 
prevalence of intractable epilepsy are somewhat uncertain (9). It is agreed on 
among the majority of references that up to 80% of people with epilepsy gain 
adequate seizure control with the use of a single appropriately selected antiepileptic 
drug used at the correct dosage and that despite the introduction of many second-
generation antiepileptic drugs (AEDs) in the past 15 years, about 20% of patients 
with epilepsy remain refractory to all available pharmacological treatments (10)even 
if they have experienced long periods with no seizures at all (11). However the 
percentage reviewed historically varied widely between 10 – 40% (11-25). 
Intractability was specifically estimated higher in very long follow-ups beyond the 
paediatric age. Difference between the reported frequencies of uncontrolled 
seizures was not only due to different geographical and socio-economical factors, 
but also for lack of a standard definition of intractable epilepsy (IE) as well (26-29). 
Failure to achieve remission pharmacologically is not always due to resistance and 
may be attributed to improper selection of an agent, poor compliance in its use, 
relapse after tapering of drugs, unavailability of the medication (27,30,31), or even 
lack of trace elements and electrolytes homeostasis (32). Identifying those children 
who are prone to develop uncontrolled seizures is critical for parental counselling 
and selecting patients for more intensive investigations and treatment, such as early 
consideration of epilepsy surgery (33). Resistance can extend even into alternative 



















Studies suggest that the newer agents are no more effective but may be somewhat 
better tolerated than the older agents (34); the pharmaco-sensitive children will 
respond well to monotherapy provided accurate recognition of the epilepsy 
semiology is made. These children can be managed in a cost effective manner with 
targeted investigations and treatment schedules. Categorizing this group allows the 
remainder of patients with epilepsy who have more complex seizure disorders to 
have access to the more costly resources.  
Early detection and intervention of children with intractable epilepsy will result in 
better outcomes for co-morbidities, seizure control and cost (both emotional and 











































Historical aspects of the definition of Intractable Epilepsy 
Concern relating to intractable epilepsy dates back to ancient Indian medicine and 
extended further when concepts about epilepsy became more developed during the 
Vedic period of 4500-1500BC and in the Ayurvedic literature of CharakaSamhita 
(dated to 400BC)(35). 
In the Babylonian description of epilepsy 2000BC there are attempts to identify early 
intractability of epilepsy:  
6. [If an epilepsy demon falls many times upon him, and on] a given day he seven 
times pursues and possesses him, his life will be spared. If he should fall upon him 
eight times his life may not be spared. 
7. [If an epilepsy demon falls many times] upon him, and for one year when he falls 
(The patient) has the fit at the (same) precise time, the situation is critical. Miqtu 
draws closest to a man at midday and it is then most serious for him. 
8. [If an epilepsy] demon falls (many times) upon him and on a given day he seven 
times pursues him and he has a fit with loss of consciousness, and if when (the 
demon) has let him go he hand of the departed spirit of a murderer. He will die (36). 
In the past, epilepsy was associated with religious experiences and even demonic 
possession. In ancient times, epilepsy was known as the "Sacred Disease" (as 
described in a 5th century BC treatise by Hippocrates (37). 
Because people thought that epileptic seizures were a form of attack by demons, or 
that the visions experienced by persons with epilepsy were sent by the gods. Among 
animist Hmong families, for example, epilepsy was understood as an attack by an 
evil spirit, but the affected person could become revered as a shaman through these 
otherworldly experiences (38). 
In most cultures, persons with epilepsy have been stigmatized, shunned, or even 
imprisoned; in the Salpêtrière, the birthplace of modern neurology, Jean-Martin 
Charcot found people with epilepsy side-by-side with the mentally retarded, those 
with chronic syphilis, and the criminally insane. Even in current times in Tanzania, 
as with other parts of Africa, epilepsy is associated with possession by evil spirits, 





















In 1857 Sir Charles Locock reported the efficacy of bromides in the treatment of 
Epilepsy (40), thus announcing the beginning of epilepsy‟s pharmacological 
treatment. In 1912 phenobarbital was shown to be effective. There was a haphazard 
release of a few drugs (for example, phenytoin, carbamazepine, and valproic acid) 
until the past 12 years when 10 new antiepileptic drugs (AEDs) drugs were 
approved for use. These newer drugs differ from the older ones in terms of 
pharmacokinetics and side-effect profiles, but there is no evidence that any are 
more efficacious in the treatment of epilepsy than the older AEDs (41). 
Over the past few decades efforts to try defining intractable epilepsy was diverse 
and not very conclusive but as approaches become more organized and 
experiences accumulate, the definition is becoming more defined supporting earlier 
referral for epilepsy surgical assessment and other alternative interventions. 
Although the concept of drug resistant epilepsy (often used interchangeably with 
„„medically refractory/intractable‟‟ or „„pharmaco-resistant‟‟) may appear self-
explanatory and obvious, a precise definition has remained uncertain. This has 
resulted in diverse criteria used by different clinicians and researchers, or even a 
lack of explicit criteria in some cases, rendering it difficult to compare findings across 
studies and to make practice recommendations (42-45). 
Since there is no agreed definition of intractable epilepsy (IE), it is not surprising that 
several diverse criterions for drug resistance are found in the literature (46, 47). 
In response to this, the international league against epilepsy (ILAE) appointed a task 
force under the commission on therapeutic strategies to formulate a proposal for a 
consensus definition of drug resistant epilepsy. 
Traditionally, therapeutic failure of three AEDs defined intractability (18, 19, 21, 44, 
48, 49, 50, 51). With many new AEDs available in recent years, it might have been 
expected that more rather than fewer drug trials would be recommended before 
determining intractability. However, several prospective case series have shown that 
a high likelihood of medical intractability can be identified after two unsuccessful 
trials, as with each AED failure, the likelihood of successful treatment with other 























The ILAE definition of Intractable Epilepsy 
There are several factors to be considered in a definition of medical intractability 
(Table 3), including the number of AED failures, minimum frequency at which 
seizures must occur to be considered intractable (daily, monthly, and so forth), 
duration of unresponsiveness to medication, epilepsy syndrome involved, causes of 
seizures in the absence of a clear-cut epilepsy syndrome, and patient age at the 
onset of seizures.(44) WHO, the International League against Epilepsy (ILAE) and 
the International Bureau for Epilepsy (IBE) are undertaking a global campaign to 
provide better information and raise awareness about epilepsy. They aim to 
strengthen public and private efforts to improve care and reduce the disorder's 
impact. A new revised classification of epilepsy exists for general practitioners and 
primary health care providers, listing simple therapies and straight-forward 
approaches for pharmacologically sensitive children with access to commonly used 
effective drugs. There has not been consistency as to the definition of the term 
“intractable epilepsy” (Table 1) (55). 







1 seizure per mo 
for ≥18 mo and ≤3 
mo seizure free 
during that time 
The outcome had to be 






At 6 mo after 
diagnosis, failure 
to be ≥3 mo 
seizure free 
Published criteria were 
not modified. This is an 
indicator of risk and not 
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seizure free 
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The ILAE appointed a task force which formulated a consensus document for a 
definition of drug resistant epilepsy. The task force comprised members with diverse 
expertise, including epidemiology, adult and paediatric epileptology, neurosurgery, 
clinical pharmacology and clinical trial design. Pertinent literature and discussion at 
relevant workshops were considered (218). 
The proposed definition stated that drug resistant epilepsy is the failure of 
adequate trials of two tolerated, appropriately chosen and used antiepileptic 
drug schedules (whether as monotherapies or in combination) to achieve 
sustained seizure freedom. Seizure freedom is defined as freedom from seizures 
for a minimum of three times the longest pre-intervention inter-seizure interval 
(determined from seizures occurring within the past 12 months) or 12 months, 
whichever is longer (56). 
For treatment response the overall framework of the definition has two „„hierarchical‟‟ 
levels: Level 1 provides a general scheme to categorize response to each 
therapeutic intervention, including a minimum dataset of knowledge about the 
intervention that would be needed; Level 2 provides a core definition of drug 
resistant epilepsy using a set of essential criteria based on the categorization of 
response from Level 1 to trials of antiepileptic drugs (tables 2 and 3). 
 








1. Seizure-free A. No 1A 
B. Yes 1B 
C. Undetermined 1C 
2. Treatment failure A. No 2A 
B. Yes 2B 
C. Undetermined 2C 
3. Undetermined A. No 3A 
B. Yes 3B 
C. Undetermined 3C 




















Table 3   Minimum dataset required to determine whether the trial of a therapeutic 
intervention is informative  
 
Nature of the intervention (e.g., type of drug, in the case of antiepileptic drug 
treatment) 
 
Mode of application (e.g., formulation, dose, dosing interval, and patient‟s 
compliance in case of an antiepileptic drug) 
 
Duration of exposure 
 
Occurrence of seizures and adverse effects during the trial period 
 
Whether there was any effort to optimize dose 
 
Reason(s) for discontinuation (if applicable) 
Unsatisfactory seizure control 
Adverse effects 
Long-term seizure freedom 
Psychosocial reasons, for example, planning for pregnancy 
Administrative reasons, for example, lost to follow up 
Financial issues, for example, cannot afford treatment 
Patient/caretaker preference 
Other reasons 






























Even though some studies suggest that epilepsy fails to come quickly under control 
with medicines in about one-third of cases, it is the definition of “uncontrolled “that is 
needed so that estimations of true prevalence can be made (57). 
It is important to predict as soon as possible after diagnosis and starting treatment, 
which children are destined to develop medically intractable seizures and be at risk 
of increased morbidity and mortality (58, 59) and which child's epilepsy will remit 
and which will be a lifelong disorder (59). 
In addition to providing parents with answers, this could allow for more aggressive 
treatment with modern antiepileptic drugs (AEDs) to obtain the maximal drug 
response to overcome drug-resistance without delay, if possible(60),if needed, early 
neurosurgical intervention in suitable cases(61). 
Early recognition and interventions would improve the lives of children with 
intractable epilepsy (62). 
 
Latency in recognizing intractability 
Up to 20years delay are described to recognise intractable epilepsy, especially for 
focal epilepsy (63).  
In a study of 333 patients latency time was 9.1 years and younger age at onset was 
strongly associated with longer latency time (51). 
Even in the most specialized epilepsy surgical centres it was estimated that it took at 
least 5 years from the onset to recognize IE when referred from non specialized 
services outside the centre; however when referred  from a  paediatric neurologist it 
took 6 .4 years and 6.6 years by the epileptologist. Much related to the duration of 
AED trials and the uncertainty of the definition (64). 
Epilepsy may not be clearly intractable for many years after onset. This is especially 



























Predictors of Intractability 
A number of prospective studies have attempted to identify factors that predict the 
risk of intractable epilepsy (IE). These studies have varied somewhat in their 
sampling (population-based versus hospital-based) and whether they included 
children, adults, or both (48). No single factor has been found to be uniquely useful 
in making accurate predictions. A combination of one or several of these factors 
may help to recognise IE. 
 
Frequency of seizures 
An average, four seizures every month, was often used as an entry criterion for 
adjunctive drug trials in drug-resistant partial epilepsy (65). 
The definition of not being seizure-free for 1 year despite treatment (11, 12) is 
reasonable to consider as IE. In the UK National General Practice Study of Epilepsy 
with a follow-up of 9 years that included childhood-onset cases, the only 
independent predictor of one year and two-year remission was the number of 
seizures experienced by the patient in the 6 months after the first seizure (66, 67). In 
support other studies found that high seizures frequency even prior to diagnosis and 
treatment was definitive risk factors for IE (11, 13, 19, 21, 22, 24, 48, 49, 60, 67). 
Frequency of seizures (the lack of a three-month seizure-free period after six 
months of treatment) is a major prognostic factor for intractability (68). 
 
Onset of seizures 
Some studies suggest that age at presentation may be a factor in the development 
of IE (19, 21, 69). Some paediatric studies have found that seizure onset in later 
childhood or adolescence appears to be more likely to be associated with IE than 
seizures with onset between the ages of 5 and 10 years.(13, 26) Onset in the 
neonatal time period is associated with IE in at least one series (13). The varying 
risk of IE by age group likely relates to the underlying pathogenesis of epilepsy that 
also varies by age and brain maturation and vulnerability (71). 
Datta et al. found that 38% of the 40 patients with an onset of seizures in the first 
year of life had uncontrolled seizures at follow-up. Early seizures onset with high 
frequency can predict long-term seizure control during antiepileptic drug treatment, 

















Frequent seizures from the onset may be the first manifestation of various epileptic 
syndromes with a wide range of severity, particularly in childhood which can be used 
to predict intractability (70).  
 
Aetiology 
The underlying aetiology and seizure classification are also important.  
Idiopathic syndromes, for both generalized and localization-related epilepsy, have a 
better prognosis than symptomatic/presumed symptomatic epilepsy in both 
paediatric and adult populations (11, 21, 22, 49, 72, 73). 
Certain paediatric epilepsy syndromes are almost invariably intractable.  
Aetiology is predictive of both seizure outcome and mortality in childhood-onset 
epilepsy (58). 
Data that symptomatic aetiology adversely affects seizure outcome are consistent 
with a MRI-based study (73). 
Several studies indicated that high initial seizure frequency and remote symptomatic 
aetiology were more common in IE (11, 12, 26, 29, 74-76). 
Epilepsies with vascular lesions may be more treatment responsive than those with 
mesial temporal sclerosis (MTS), cortical dysgenesis, or dual pathology (19). MTS 
have some of the highest rates of medical intractability (18, 19). 
 
Seizure type 
Some studies did not find seizure type as a predictor of IE (13, 77). 
It was found that the seizure types with the poorest control were infantile spasms, 
atypical absence, and myoclonic seizures (78).  
Other studies found that myoclonic seizures or infantile spasms as initial seizure 
type are an independent predictor of IE (79, 80). 
Febrile seizures were generally not found to be associated with intractability (11, 79) 
although this was contended (24). 
 
Initial response to treatment 
Response in the first 6–12 months was shown to be predictive of outcome in a study 
of new-onset epilepsy in children (81).One concept is that intractability can be 
predicted according to the initial response to medication trials (48).The response to 
the first AED trial is the most important and consistently cited predictive factor (11, 

















While more than half of patients respond to the first AED prescribed, less than 20 
percent are likely to respond to subsequent drug trials. With each number of failed 
AED trials, the risk of IE increases (21, 27, 47, 82). 
In contrast with those presented above, It was found that nearly one in five children 
whose epilepsy is initially well controlled later develop drug resistance (83) and 
medical intractability may develop many years after the initial onset (51). 
A few mechanisms are proposed as secondary pathogenesis (219).   
 
Other predictors of intractability 
Occurrence of status epilepticus either at the onset or subsequently was shown to 
be an independent predictor of intractability (11, 21, 22, 48, 49, 72). 
An abnormal neurologic examination and/or developmental delay are also identified 
as risk factors for IE in some studies (13, 22, 84, 85). 
The first abnormal EEG is another predictive factor for IE (21, 28, 49). Other studies 
do not support this (48, 86). 
Other factors which may be considered as predictors include longer duration of 
epilepsy (60), family history of epilepsy (21, 22, 24), abnormal brain CT scan (28), 
history of neonatal seizure, and microcephaly (87). 
 
Predictors of delayed intractability  
Several studies show that epileptic patients may enter remission early in their 
course and develop IE later, after a period of remission that in some cases is a long 
as several years (63, 83, 88, 89). Factors that predict a later development of IE are 
not well defined. 
. 
Measuring intractability 
Various rating systems are available to measure intractability. These definitions take 
into account the duration of epilepsy and response to antiepileptic drugs and do not 
take into account the epileptic syndromes. These definitions are useful in identifying 
older children with intractable epilepsy but not in infants and younger children with 
severe epileptic encephalopathies who should be considered IE from the beginning 
(79).  
The Nova Scotia scoring system was very accurate when was used to predict 




















Apparent intractability  
Non epileptic seizure constitutes 25-50% of cases of IE referred to a Neurologist or 
epilepsy centre (92). It is important to differentiate true versus apparent medical 
intractability. Reasons for apparent intractability include: 
1)  Wrong epilepsy diagnosis. One study showed that as many as 26 percent of 
individuals thought to have IE were incorrectly diagnosed most often as a result 
of incomplete history-taking and/or EEG misinterpretation (90). 
2) An incorrect seizure type/ syndrome diagnosis leading to incorrect drug choice 
(18). In some instances, a narrow-spectrum AED can worsen seizure frequency 
(42, 90). With an inappropriate dosage (90) in contrast, seizures can also occur 
with AED toxicity (42).  
3) Noncompliance in one case series, 71 percent of patients reported at least 
occasional dose omissions, and 45 percent reported a seizure after a missed 
dose (91). Providing a non-judgmental setting in which to elicit this history is 
important. Support from family members and physicians increases medical 
compliance (18).  
 
Pathogenesis 
1) Alteration in neural structure & circuitry: Pathologic and neuroimaging studies 
demonstrate an evolving process involving glial proliferation and dendritic 
sprouting with synaptic reorganization (21, 93). Alterations in neural circuitry 
conceivably may lead to an epileptic network that becomes drug resistant over 
time.  
2) Alteration in drugs receptors, transporters and pharmacokinetics: Studies in 
animal models found drug-resistant temporal lobe epilepsy associated with 
altered expression of multidrug transporters, altered expression of AED targets, 
as well as morphologic alterations in the hippocampus (47). Distinguishing which 
of these findings is the cause versus the effect of IE, and if it has relevance in 
human IE, is part of ongoing investigations. While one study found an 
association with a polymorphism in the drug transporter gene (ABCB1 or MDR1) 
and drug-resistant epilepsy (94, 220) others did not (95, 96). Another hypothesis 
proposes that over expression of these multidrug transporters is induced by 
recurrent seizures, emphasizing the importance for early aggressive seizure 

















3) Other alterations, acquired or inherited, of AED absorption, metabolism, 
receptor-binding, and blood brain barrier permeability are also potential causes 
of pharmacoresistance (97, 98, 221). 
 
Underlying aetiologies  
Aetiology of the epilepsy was found to be a strong predictor of intractability. 
The more recent report of the ILAE Commission on Classification and Terminology 
reclassified epilepsy based on three aspects including aetiology (genetic, 
structural/metabolic or unknown) (99). The aetiology of intractable epilepsy varies 
with age and is different among various geographic regions, and, importantly, with 
the thoroughness of investigative technology used to unravel the aetiology of 
epilepsy (11, 78, 100). Birth asphyxia was the leading cause of intractable epilepsy. 
In resource poor countries, common causes of epilepsy include perinatal asphyxia, 
infections of the central nervous system (meningitis, central nervous system 
tuberculosis) and parasite infestations, for example neurocysticercosis. These 
findings could be explained by the poor socioeconomics in these countries (101). 
Neurocysticercosis was defined as the leading cause of intractable epilepsy in other 
studies (101-103).These findings are in contr st with the reports in developed 
countries in which perinatal insult (104) and cortical developmental abnormality 
(105) are the major causes. Seizures are common complication of HIV but occur 
from multiple causes (106-109). 
 
Response to Pharmacology 
It was suggested that failure of seizures to respond to a single AED is a strong 
predictor of medically refractory epilepsy (27). Another definition of intractability is 
the occurrence of one or more seizures per month on follow up of one year or more 
with an adequate trial of two first line AEDs (for example carbamazepine and 
valproate) and one or more of the newer second line antiepileptic drugs (27). 
When 2 AEDs for the correct seizure type and in adequate doses fail, there is only a 
5–10% probability of achieving seizure control with a third drug (45, 48, 49, 110). 
Another approach scores intractability by the number of drugs tried in mono and 
polytherapy regimens (13). 
In two important studies, one by Mattson and colleagues (111) and the other by 
Kwan and Brodie (48) seizures are not controlled with a single AED, then adding a 
second will make them seizure-free only about 10% of the time. The second drug 

















polypharmacy can lead to drug interactions (112) that limit effectiveness or increase 
side effects of another drug. Therefore, simplifying medications is sometimes the 
preferred option even this may seem to contradict the target of aim seizure control.  
It is important to always ensure optimization of pharmacology has occurred before 
judging its failure. 
HIV-positive patients present special problems, especially with respect to drug-
disease and drug-drug interactions. The older AEDs are protein-bound and largely 
depend on the cytochrome p450 system for their metabolism. The newer AEDs may 
be safer in patients on antiretroviral drugs. However, they are expensive, an 
important consideration in resource poor countries (113). 
 
Investigating IE 
Patients with IE should have further testing to confirm the diagnosis of epilepsy and 
also to better define the epilepsy syndrome and underlying classification in order to 
best direct treatment (114).The evaluation of IE should include video 
electroencephalography (EEG) monitoring, magnetic resonance imaging (MRI) and 
often a metabolic workup (115). 
 In some series, more than 25 percent of individuals referred for monitoring for 
refractory epilepsy are found to have no epileptic events, usually psychogenic 
events (90). EEG monitoring can also aid in seizure classification and is used for 
pre-surgical evaluation of IE patients. By the time a patient is considered to have IE, 
an MRI study will usually have been performed. In many cases, this should be 
repeated, particularly if the original study was unrevealing. Not all MRI findings are 
relevant and they should be correlated with the patient's seizure semiology and EEG 
results; some potentially epileptogenic lesions may be incidental. Children with 
medically intractable epilepsy should be considered for epilepsy surgery if the 
epileptogenic zone is reasonably localized with non-invasive pre-surgical evaluation 
(116, 117). Presence of visible MRI lesion not only warrants surgical candidacy, but 
also predicts a favourable surgical outcome(118-121).In the absence of a causative 
lesion on MRI, an epileptogenic focus can sometimes be defined in patients with 
localization-related epilepsy using advanced neuroimaging techniques including 
positron emission tomography (PET), single photon emission computed tomography 
(SPECT), magneto-encephalography (MEG) and magnetic source imaging (MSI). 
Data suggest that MEG and Subtraction Ictal SPECT Co-registered to MRI 
(SISCOM) are better tools for lobar localization than statistical parametric mapping 

















epilepsy. A multimodality approach may improve surgical outcome as well as 
selection of surgical candidates in patients without MRI abnormalities (122). 
The overall seizure-free outcome was 50% when all 3 non-invasive modalities were 
used. This seizure-free outcome compares well with other published series of 
nonlesional epilepsy (120, 123). The consistency in identifying the same surgically 
remedial focus of all tests including MSI, FDG-PET, and ictal SPECT, predicts 
increased odds for seizure free outcome after surgery (124). 
 
Management of Intractable Epilepsy 
Resective epilepsy surgery is the treatment of choice for medically resistant lesional 
partial epilepsy as this has the most likely chance of producing remission. Further 
AED trials, vagal nerve stimulation, and the ketogenic diet can reduce seizure 
frequency and improve quality of life but are more likely to be palliative, rather than 
curative treatment options (114, 125, 126). 
 
Epilepsy surgery 
Epilepsy surgery should be considered in appro riate patients with IE when seizures 
are sufficiently frequent or severe enough to impact on the patient's quality of life 
(127).Early recognition and interventions would improve the lives of patients with IE 
(62). Resective epilepsy surgery has the best-established efficacy for individuals 
with lesional temporal lobe epilepsy (128). Patients with concordant abnormalities in 
one temporal lobe on MRI and EEG have a rate of seizure remission as high as 90 
percent (129, 130). Patients with non-lesional temporal lobe epilepsy also have a 
high remission rate with surgical therapy. The efficacy is highest in patients in whom 
EEG and another imaging modality (e.g. SPECT, MEG) reveal a consistent location 
of the epileptic focus. 
Other surgical treatments (lobar and multi-lobar resections, hemispherectomy, 
corpus callosotomy, multiple subpial transections) are sometimes employed for 
palliative treatment in children with catastrophic epilepsy syndromes.  
Young children with this intractable disorder may be better candidates for 
aggressive surgical treatment because of the increased neuroplasticity of the 
developing brain (117, 131-133). 
Successful epilepsy surgery improves life expectancy and health-related quality of 
life, whilst reducing health care costs as a result of reduced hospital admissions, 

















Surgical intervention for intractable epilepsy may provide a good opportunity to 
prevent irreversible decline of intelligence and cognitive function (136, 137). 
Some IE cases are highly responsive to surgery, and early surgical intervention is 
highly cost-effective for patients with surgically remediable syndromes and there 
would be no need to pursue exhaustive drug trials with these patients (138). 
Epilepsy surgery (ES) is addressed in relation to economic classifications of 
thousands of patients who could benefit from epilepsy surgery, but inequalities in 
healthcare provision mean that ready access to surgical facilities is largely 
restricted. It was found that ES is nonexistent in 98% of African countries, 86% of 
countries of the Western Hemisphere, 82% of Middle East countries, 76% of Asian 
countries and in 58% of European countries. The surgical outcomes achieved in 
developing countries are similar to those in the developed world, but at a fractional 
cost. To internationalize ES, outcome, cost and savings from care, evolution of 
assessment methodology is needed. Also needed is general support from the 
developed world (139). 
 
Non Surgical management of IE 
Steroids are effective in West syndrome (WS), Lennox Gastaut syndrome (LGS) 
and other IE of childhood (140). Adrenocorticotropic hormone (ACTH) was initially 
introduced in the treatment of WS (141, 142). Ganaxolone is another synthetic 
neurosteroid analogue which is of use in WS. It has potent and selective positive 
allosteric modulator of gamma-Aminobutyric acid-A (GABAA) receptors 
(143).Immunoglobulins in IE are of unknown efficacy and unknown mechanism of 
action, a randomized multicentre double blind trial was started in 1993 including 
patients with WS and LGS. These showed a trend in favour of Intra-venous 
Immunoglobulin (IVIG) but lacked statistical significance (144). Use of pyridoxine in 
pyridoxine deficiency and dependency IE is self explanatory and well established 
and further it was found that the use of pyridoxine and pyridoxical phosphate in 
idiopathic IE to be effective in some studies (145-150). 
Since 1921 Ketogenic diet (high fat, low protein and carbohydrate diet) is used in the 
treatment of children with IE. There has been renewed interest for this over the last 
decade. The cost for initiation is high and it was found to be effective in all types of 
IE in children (Generalised, partial & infantile spasms) (125, 151-153). 
It may be continued for 1-2 years, prospective study of 150 children with intractable 
epilepsy who initiated the diet at Johns Hopkins found that 83 remained on the diet 

















These children were reassessed 3–6 years after their diet initiation and 78% 
continued to have a >50% reduction in seizure frequency as well as a decrease in 
medications(152, 155).Class IV literature evidence on the effectiveness of ketogenic 
diet in the treatment of IE continue to emerge each day (222-230). Atkins diet 
restricts carbohydrates but does not restrictive consumption of calories or proteins. 
This was originally used for weight reduction. There is a preliminary report of its 
effectiveness in reducing seizures in IE(156).In  case series a modified Atkins diet 
reduced seizure frequency by 50 percent or more in half of patients with IE (157).  
 
Vagal nerve stimulation (VNS) is approved for adjunctive treatment of medically 
intractable partial onset seizures in adults and children. Approximately 30 to 40 
percent of patients achieve a greater than 50 percent reduction in seizure frequency, 
a benefit that is sustained over time. Serious adverse events are rare. 
VNS is a valid treatment option for patients with well-documented IE, who are either 
opposed to epilepsy surgery, or who are not candidates, or whose seizures were not 
substantially improved by prior epilepsy surgery and in children who failed ketogenic 
diet (158-160). 
 
Deep brain stimulation is sub-cortical stimulation paradigms which target the anterior 
and centromedian thalamic nuclei, the subthalamic nucleus, the caudate, and the 
cerebellum (161, 162). Controlled studies found that stimulation in these sites 
reduces seizure frequency by 50 percent or more in some patients (162). 
In a randomized clinical trial of stimulation in the anterior nucleus of the thalamus in 
110 patients with drug-resistant epilepsy, stimulation therapy was associated with a 
29 percent reduction in seizure and in 54 percent there was reduction of at least 50 
percent.(163).Two small controlled trials found that stimulation of the hippocampus 
reduced seizure frequency in patients with mesial temporal lobe epilepsy (164-166). 
Another approach under investigation employs a closed-loop cortical stimulation unit 
coupled to a seizure-detection system. Studies found that this treatment may be 
associated with a substantial reduction in seizure number, intensity, and duration. A 
clinical trial is underway and results expected in 2011(167-172). 
Transcranial magnetic stimulation are low frequency transcranial magnetic 























Associated co-morbidities and Outcome of IE 
It is important to understand the impact of IE in the context of the individual's life, 
schooling, and other psychosocial circumstances (114). 
Epidemiological information from Olmstead County found predictors of outcome of 
childhood epilepsy to include neurological or intellectual deficit (14, 174). 
Quantitative MRI evidence shows an adverse effect of early-onset epilepsy on brain 
structure (reduced volume of the corpus callosum or reduced whole brain white-
matter or grey-matter volumes) in patients with childhood-onset partial epilepsy 
compared with adult-onset partial epilepsy(175, 176). 
Catastrophic epilepsies beginning during the childhood developmental stage halt 
cognitive and social development with permanent long term effects (177). 
Syndromes that are refractory to antiepileptic drugs are invariably associated with 
psychomotor co-morbidities (177-181).IE is also associated with disability and 
diminished quality of life (21, 50). Nonfatal injuries are also common in those 
patients with IE. These include head injury, burns, and fractures, among others; 
most are seizure-related (182). 
Several studies explored the economical burdens of IE and some even have 
demonstrated the annual cost for patients with epilepsy to be very high and that IE 
contributes a substantive proportion of this cost (191-194). 
 
Individuals with IE have an increased mortality rate (183-185). Sudden unexplained 
death in epilepsy patients (SUDEP) was found to be 24 to 40 times more likely 
among children with IE(185-187). Very few studies of death in epilepsy have 
included a substantial number of children with a long follow-up since the onset of 
their epilepsy (59, 177, 188, 189).In these studies, mortality increased with time and 
most of the deaths were related to the presence of a severe neurological deficit, 
remote symptomatic aetiology or both and not directly to the seizures themselves. 























Local experience of IE  
Concerns about Epilepsy within South Africa reflected in the literature as early as 
1964 under the title of “Epilepsy in South Africa an urgent problem” (195). In a 
publishment relating to Epilepsy and the law in South Africa in 1970(196), to 
concerns of ILAE commission on the availability of AEDs and their non 
homogeneous distribution and availability in contrast to older and less effective 
drugs like Phenobarbital (197). 
A local study revealed in over half of children onset of epilepsy was before the age 
of 2 years with the majority being symptomatic, 55% were intellectually 
handicapped. Acceptable seizure control was achieved in 71% of them and that 
68% were treated with a single AED. It and other studies in the Western Cape 
concluded that a reduction in the incidence of epilepsy in the community could be 
achieved by improvements in obstetric/neonatal and reducing meningitis, 
tuberculosis, neurocysticercosis, and cerebral trauma services and by the raising of 
living standards (198, 199). 
 
Christianson et al worked on determining the prevalence of epilepsy and its 
associated disabilities in rural South African children aged 2-9 years found the 
lifetime and active prevalence of epilepsy in these children were 7.3/1,000 and 
6.7/1,000 respectively and associated developmental disability to be 71.4% (16.3% 
Moderate to severe) in affected children and that more than a half of the children 
with epilepsy did not receive AEDs (4).  
 
Several Searsia species (Anacardiaceae) are used in South Africa traditional 
medicine to treat epilepsy. These plants may combine one or more γ-aminobutyric 
acid (GABA) (A) agonists with one or more NMDA antagonists, thus representing an 
efficient treatment for epilepsy (200). 
 
Over the past 5 years, more than 250 patients have had successful epilepsy surgery 
in Cape Town (two university-affiliated neurology departments and a private 
epilepsy centre) with patients becoming seizure-free and with improvement in their 
quality of life (201).The authors current database now including some 600 patients 
less than 50 were managed in the government sector and 25-30 were children 


















There were no studies conducted on children with intractable epilepsy in South 
Africa. In a survey of the understanding of the definition of intractable epilepsy 
among paediatric neurologists from across the country at the Complex Epilepsy day 
meeting, Johannesburg August 2010, diversity in defining intractability was found. IE 
was defined very closely to the recent ILAE definition as the failure of adequate trials 
of two to three (4 specialists used the two drug definition and 3 used the three drug 
definition and 3 did not specify the number of drugs) appropriate AEDs whether as 
mono-therapies or in combination to achieve seizure freedom. One definition 
included a time frame of 6 months and another considered encephalopathy as an 
association (Table 4). 
Table 4   Definitions of Intractability by paediatric neurologist working in different 
regions in South Africa 
Definition No. of 
drugs 
Region 
 Still fitting by the time the third drug is tried alone or in 
combination. 
3 Johannesburg 
Seizures, Non responsive to 3 drugs at optimal doses.  3 Johannesburg 
 Failure to control seizures adequately after use of 3 
AED‟s.  
3 Johannesburg 
 Fitting uncontrollably and the need to add a 3rd drug.  2 Johannesburg 
Failure of 2 drugs adequate doses and have to add a 
third drug. Also a time frame of 6 months.  
2 Johannesburg 
Uncontrolled seizures, not controlled by poly 
pharmacology 2 or more drugs and you have reached a 
point of frustration may /may not be part of an epileptic 
encephalopathy.  
2 Johannesburg 
No decrement in seizures with use of adequate doses 
of appropriate anticonvulsant.  
NS Johannesburg 
Not responsive to 2-3 drugs, frequent seizures despite 
optimal treatment and frequent status despite treatment. 
2-3 Cape Town 
Failure of 2 appropriate, adequate drugs in doses and 
duration.  
2 Cape Town 
Failure to control seizures with standard antiepileptic 
therapy at appropriate dosage.  
NS Cape town 
 
Pharmacoresistant to 2 drugs in optimal dose after 





















Intractable Epilepsy in South African children (The study) 
 
Aim 
To identify the prevalence and characteristics of children with intractable epilepsy 
managed in a tertiary referral service.  
 
Objectives 
1. To identify the prevalence of intractable seizures in a tertiary setting. 
2. To define the patient demographics and seizure types, underlying aetiologies 
and associated co-morbidities. 
3. To assess the effectiveness and relevance of the current International 
League against Epilepsy (ILAE) guidelines for intractable seizures compared 
to previous perceptions in our context. 
4. To identify key markers to allow early recognition of intractable epilepsy 
5. To identify key needs of patients with intractable epilepsy in our context 
6. To identify which patients may be remedial to interventions other than anti-





A retrospective case note review, following prospective identification of the group. 
 
Subjects 
Patients attending the Epilepsy service at Red Cross War Memorial Children‟s 
Hospital (RCWMCH) in a 6 month period (August 2010 to February 2011) were 
prospectively screened for those who complied with the ILAE definition of 
intractability and the previous standard definitions of intractable epilepsy. This group 
was then enrolled in the study if they once met the inclusion and exclusion criteria, 
and parental / carer consent was obtained.  
From the literature at least 20% of the patients with epilepsy were expected to 
respect these criteria (10- 25), Based on clinic's statistics about 100 children with 

















study aimed to recruit 400-600 patients with epilepsy with a minimum of 50 patients 
meeting the definition of intractable epilepsy. This figure is similar to that described 
in other single centre studies (202). 
 
 
Data Collection procedure 
All out-patients were screened using the standard neurology statistics template 
(Appendix 1) with the additional definition of intractable seizures included and a tick 
box for the attending clinician to use.  
The study was explained and written consent (and assent when possible) taken by 
the attending clinician (Appendix 2, 3).  
Medical folders of the patients were identified and reviewed for the additional 
necessary data (Appendix 4). 
 
Inclusion criteria: 
 Age: 0-18 
 Failure of adequate trials of two tolerated, appropriately chosen and used 
antiepileptic drug schedules (whether as monotherapies or in combination) to 
achieve sustained seizure freedom ((Seizure freedom is defined as freedom 
from seizures for a minimum of three times the longest pre-intervention inter-
seizure interval (determined from seizures occurring within the past 12 
months) or 12 months, whichever is longer)). 
 
Exclusion criteria 
 Still initiating medication 
 Non-compliance 
 Neurodegenerative disorder 
 Acute illness (e.g. Tuberculosis, Meningitis) 
 
Data were captured using standardized form created for this study (Appendix 4) and 




This included age, gender and ancestry. Ancestry as a demographic variable was 

















patient into broad categories of African, European, Asian, and Mixed. The address 
was entered for all patients with intractable epilepsy to identify whether they are 
local are referred from outside the metropolis. 
 
Epilepsy Semiology  
The semiology of the epilepsy type was identified among both groups (Intractable 
and non intractable) and compared using the latest ILAE classification in 2009 (99). 
Definition of Intractability  
Having met the inclusion and exclusion criteria patients ticked as intractable 
epilepsy were further verified using the ILAE definition of intractability and all 
patients not ticked were also reviewed to identify possible missed cases and to 
correct their status.  
 
Onset of epilepsy and frequency among the intractable group. 
The onset of epilepsy, frequency and duration of seizures, provoking factors and 
family history of seizures was obtained as part of the background information.  
 
Duration of time to recognize intractability. 
Whether the confirmation of intractability was made prior to or after the 
commencement of this study was entered, i.e. whether the study itself resulted in 
the recognition that the child had intractable epilepsy. The total duration of time 
taken from the onset of epilepsy to label the patient as intractable was recorded.  
 
Co-morbidities and aetiology 
The occurrence of status epilepticus, neuroregression, intellectual disability, 
behavioural problems, developmental problems, learning difficulties and social 
problems were entered. 
A variety of possible underlying and co-morbid conditions was entered including 
perinatal events, cerebral palsy, metabolic derangement, meningitis, structural brain 
malformations, vascular events, head trauma, HIV, Tuberculosis meningitis, 
Neurocutaneous disease (except TS), and clinical findings such as microcephaly, 
Macrocephaly, dysmorphism, bulbar dysfunction, speech, hearing and visual 
problems. In addition to other medical event that might be related to patients events 
or not gastro-oesophageal reflux, Gastrosotmy, fractures, allergies, infections, non-



















Whether patients had an EEG, video EEG telemetry, ultrasound of the head, CT 
scan, MRI, SPECT or Metabolic workup (ammonia, blood gas, lactate, glucose, , 
pyruvate, glycine, amino and organic Acids screens on urine, blood and cerebral 
spinal fluid as appropriate)data was entered. 
 
Management and pharmacological treatment 
The number of AEDs and compliance with medication in general that was used was 
recorded, as well as the name, dose, frequency, compliance with the specific 
medicine, duration of use and reason for discontinuation if a drug was discontinued. 
The occurrence of seizures or side effects during each AED use if not discontinued 
and whether the agent was optimized or not. 
Other interventions. 
Use of ACTH, prednisone, pyridoxine or other vitamins or elements was entered. 
Other interventions if any was included such as the ketogenic diet with its duration, 
VNS, epilepsy surgery or others (We did not count patients who were either offered 
ketogenic diet or surgery and refused or were not compatible after the workup).  
 
Ethics/consent  
The protocol was submitted to the Red Cross War Memorial Children‟s Hospital 
Research Committee and to the University of Cape Town Committee for Human 
Health Sciences Ethics Committee for review. Approval to conduct the study was 
granted (Appendix 5). 
Written consent was taken from the caregiver, and assent from the child when 
possible, giving approval to enrol the patient, access patient medical folder data and 
possibly verbally communicate with the caregiver in the future if specific data is 
needed. The caregiver was informed that the study is planned to be published in the 
peer reviewed literature. The individual information will remain confidential i.e. the 
nature of the study with grouped data will not allow the patient to be recognized.  If 
the study identifies new interventions which could be in the patient‟s interest, this will 
be communicated to the caring clinician. 
 
Costing  
Dr Hani Alkhaldi is the principal investigator. There was no additional cost to the 



















Red Cross War Memorial Children‟s Hospital is a governmental funded health 
facility located in the Western Cape Province of South Africa. It is a tertiary referral 
centre for the region. This province is inhabited by approximately 5.2 million people, 
2 million of whom are children aged 0 to 19 years of which 49.8% are males and 
50.2% are females (203). Approximately 29% of the population of the Western Cape 
Province is composed of people of African ancestry. Those of mixed descent 
comprise approximately 51% of this population, while the proportion of those of 
European descent is estimated to be 19% (204). 
At Red Cross War Memorial Children‟s Hospital the department of Paediatric 
Neurology and Neurophysiology run a weekly Epilepsy clinic reviewing 30 to 35 
children (Department statistics). Children attending these clinics must be considered 
to have epilepsy. Multiple services are involved in their management including 
neurophysiology, neuroimaging, nursing, laboratory, developmental clinic, cerebral 
palsy clinic, physiotherapy, occupational therapy, speech therapy, pharmacy, 




Normally distributed data were summarised using mean (standard deviation, s.d.); 
otherwise the median (interquartile range, IQR) was used. These results were 
presented in the form of charts and tables as applicable. We used the Shapiro-Wilk 
W test to check for normal distribution of any data. Data were analyzed as follows, 
proportions using Chi-squared ( 2), means using T-test, medians using Wilcoxon 
test (Mann-Whitney) whenever appropriate. 
All tests were two sided. A p-value < 0.05 was considered significant. Data were 
analyzed using Stata/IC 11.1 (StataCorp LP, 4905 Lakeway Drive, College Station 
TX 77845, USA) for Windows software. 
The Statistical analyses performed including exploring the relationship between 
intractability and variables such as gender, age, ancestry, number of medications, 






















Enrolment of patients in the study 
Out of 5173 patients with neurological diseases in Neurology data base of Red 
Cross War Memorial Children‟s Hospital at the time when study was concluded, 
2741(53%) had Epilepsy (Red Cross Neurology data base, March 2011). The 
Epilepsy clinic is visited by an average of 103 patients per month and during the 6 
month period of the study 543 patients with epilepsy visited the clinic (Red Cross 
Neurology Epilepsy clinic stats, August 2010-February 2011). After reviewing the 
group 8 patients were excluded as they were older than 18 years of age and from 
the remaining 535 patients a further 14 patients were excluded because of 
incomplete data. From the recruited final 521 patients, 110 were identified by the 
clinician tick sheet as “intractable” but based on the study inclusion criteria 9 
patients were found not to comply nor met the ILAE definition and removed, in 
addition 3 from the “non-intractable” group were in fact considered to have IE and 
was added (n=104).  A further 8 patients were excluded from the IE group and the 
whole study because of non-compliance. As a result our final total number of patient 
enrolled in the study was 513 and among which we when left with 96 children with 
intractable epilepsy. 
Figure 1   The enrolment of Children with Epilepsy in the study 
 
 
Definition of Intractability  
A total of 96 patient met the ILAE definition of intractable epilepsy constitute 18.7% 
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Out of the 513 Children with epilepsy, 281(55%) were males and 232 (45%) were 
females. When analyzed according to intractability there was no statistical difference 
between children with intractable epilepsy and those who are not intractable, 
considering sex distribution (p value 0.6). 
 
Table 5   Relationship between gender and intractability 
Gender Intractable (%) Not Intractable (%) Total (%) 
Female 41 (43%) 191 (46%) 232 (45%) 
Male 55 (57%) 226 (54%) 281 (55%) 
Total 96 (100%) 417 (100%) 513 (100%) 
Pearson 2 = 0.3018, 1 degree of freedom, p = 0.6 
 
Figure 2   Relationship between gender and intractability 
 
 
Mixed ancestry predominance 58%, African 38%, European 4% is observed when 
looked at the total number and there was no significant statistical difference between 



























Table 6   Relationship between ancestry and intractability 
Ancestry Intractable (%) Not Intractable (%) Total (%) 
African 39 (40.6) 158 (37.9) 197 (38.4%) 
European 5 (5.2) 13 (3.1) 18 (3.5%) 
Mixed 52 (54.7) 246 (58.0%) 298 (58.1%) 
Total 96 (100%) 417 (100%) 513 (100%) 
Pearson 2 = 1.4372, 2 degrees of freedom, p = 0.5 
 




The patients were grouped according to age at the time of the study into 4 
categories 0-1 years, 1 to 2 years, 2-12 and 12-18 years (Table 7) 
Table 7   Intractability by age categories 
Age in years Intractable (%) Not Intractable (%) Total (%) 
0 -1 0 (0.0%) 5 (1.2%) 5 (1.0) 
1-2 5 (5.2%) 15 (3.6%) 20 (3.9%) 
2-12 73 (76.0%) 304 (72.9%) 377 (73.5%) 
12-18 18 (18.8%) 93 (22.3%) 111 (21.6%) 
Total 96 (100%) 417 (100%) 513 (100%) 






























Figure 4   Comparing age categories 
 
Median age of the non-intractable group was 8.5 years (minimum 7 months, 
maximum 17.8 years, mean 8.5 years, standard deviation (s.d.) 4.1), for the 
intractable group it was 7.9 years (minimum 1 year, maximum 16.7 years, mean 7.9, 
s.d. 4.23).  Comparing median ages using the Wilcoxon (Mann-Whitney Test 
showed no significant difference by intractability (z=1.329, p=0.2). 
 
89.6% of the children with intractable epilepsy lived in the local metropolis. However 
10.4% travelled from outside Cape Town. 
 
Epilepsy Semiology  
The most recent ILAE classification was used to review the semiology of our cohort 
(99).Among the IE group the most predominant syndrome was Lennox-Gastaut 
syndrome (27.1%) followed by Epilepsy with myoclonic atonic seizures (Doose 
syndrome) (13.5%), West syndrome (Infantile spasms) (12.5%), Dravet syndrome 
(SMEI) (2.1%) and Ohtahara syndrome (EIEE) (2.1%). 
Focal seizures with impairment of consciousness/responsiveness affected 31.2% of 











































Table 8    Semiology according to the recent ILAE classification 
Semiology Intractable (%) Not Intractable (%) Total (%) 
Absence Epilepsy, Atypical 0 (0.0%) 6 (1.4%) 6 (1.1%) 
Early onset benign childhood occipital 
epilepsy (Panayiotopoulos type) 
0 (0.0%) 2 (0.5%) 2 (0.4%) 
Benign epilepsy with centrotemporal 
spikes (BECTS) 
0 (0.0%) 3 (0.7%) 3 (0.6%) 
Benign familial infantile seizures 0 (0.0%) 1 (0.2%) 1 (0.2%) 
Benign infantile seizures 0 (0.0%) 1 (0.2%) 1 (0.2%) 
Benign familial neonatal seizures 
(BFNS) 
0 (0.0%) 1 (0.2%) 1 (0.2%) 
Childhood absence epilepsy (CAE) 0 (0.0%) 18 (4.3%) 18 (3.5%) 
Focal Seizures Without impairment of 
consciousness/responsiveness 
0 (0.0%) 19 (4.6%) 19 (3.7%) 
Focal Seizures With impairment of 
consciousness/responsiveness 
30 (31.2%) 138 (33.1%) 168 (32.8%) 
Focal Seizures Evolving to a bilateral, 
convulsive seizure 
5 (5.2%) 3 (0.7%) 8 (1.6%) 
Autosomal-dominant nocturnal frontal 
lobe epilepsy (ADNFLE) 
0 (0.0%) 4 (1.0%) 4 (0.8%) 
Febrile seizures (FS) 0 (0.0%) 3 (0.7%) 3 (0.6%) 
Generalized Tonic Clonic Seizers 5 (5.2%) 111 (26.6%) 116 (22.6%) 
Febrile seizures plus (FS+) 0 (0.0%) 28 (6.7%) 28 (5.5%) 
Gelastic seizures 0 (0.0%) 1 (0.2%) 1 (0.2%) 
West syndrome 12 (12.5%) 33 (7.9%) 45 (8.8%) 
Lennox-Gastaut syndrome 26 (27.1%) 10 (2.4%) 36 (7.0%) 
Epilepsy with myoclonic atonic 
seizures (MAE) 
13 (13.5%) 12 (2.9%) 25 (4.9%) 
Landau-Kleffner syndrome (LKS) 0 (0.0%) 2 (0.5%) 2 (0.4%) 
Juvenile myoclonic epilepsy (JME) 1 (1.0%) 2 (0.5%) 3 (0.6%) 
Familial focal epilepsy, variable foci 0 (0.0%) 2 (0.5%) 2 (0.4%) 
Ohtahara syndrome 2 (2.1%) 1 (0.2%) 3 (0.6%) 
Dravet syndrome 2 (2.0%) 2 (0.5%) 4 (0.8%) 
Myoclonic epilepsy in infancy 0 (0.0%) 2 (0.5%) 2 (0.4%) 
Mesial temporal lobe epilepsy 0 (0.0%) 12 (2.9%) 12 (2.3%) 




















Localization of epilepsy  
In relation to localization of seizures, 43.8 % were localized in the non intractable 
group compared to 36.5 % in the IE group (p 0.2). 
 
Table 9   Semiology by localization of seizures 
Semiology Intractable Not Intractable Total 
Localized 35 (36.5%) 183 (43.9%) 232 (45.2%) 
Generalized 61 (63.5%) 234 (56.1%) 281 (54.8%) 
Total 96 (100%) 417 (100%) 513 (100%) 
Pearson 2(1) =1.7613, 1 degree of freedom = 0.2 
 
Epilepsy Syndromes 
We looked at the Epilepsy syndromes that were not labelled as benign in the new 
ILAE classification (West syndrome, Lennox-Gastaut syndrome, Epilepsy with 
myoclonic atonic seizures, Landau-Kleffner syndrome (LKS), Juvenile myoclonic, 
Ohtahara syndrome, Dravet syndrome) and we found that 57.3% of Children with IE 
had a Non benign epilepsy syndrome compared to only 14.4% in the non-intractable 
group (P <0.05). 
 
Table 10 Semiology by Epilepsy Syndromes 
Semiology Intractable Not Intractable Total 
Non Benign Epilepsy syndrome 55 (57.3%) 60 (14.4%) 115 (22.4%) 
Not Syndromic 40 (41.7%) 285 (68.4%) 325 (63.4%) 
Benign Epilepsy syndrome 1 (1.0%) 72 (17.2%) 73 (14.2%) 
Total 96 (100%) 417 (100%) 513 (100%) 
 
Onset of Epilepsy 
Onset of Epilepsy and frequency of epilepsy among the intractable group 
The onset of epilepsy minimum was 3 days of age, maximum 12 years, mean of 























Figure 5   Age of onset in patients with IE 
 
 
Seizure frequency at onset was analyzed per month and showed a minimum of 
1event every  months, Maximum 600 events per month, Mean of 58 events monthly 
(s.d. 108 /month, p25 3 / months, Median 4 / month, p75 66 / months). 
Figure 6   Seizure frequency at onset in patients with IE 
 

















Seizure type at onset was also reviewed, 26% were generalized tonic clonic, 23% 
focal seizures with impairment of consciousness/responsiveness, 21% febrile 
seizures, 15% infantile spasms, 8% focal seizures with impairment of 
consciousness/responsiveness, 5% myoclonic seizures, 2% atonic seizures, and 
1% focal seizures evolving to a bilateral, convulsive seizures. 
 
Frequency of seizures amongst children with IE 
Analysis frequency of seizures among IE group at the time of the study showed a 
minimum of 1 event every 3 months, with a maximum of 900 events per month(30 
events daily), mean of 60 events monthly (2 events daily) (s.d.120 /month, median 
12 per month) 
Figure 7   Frequency of seizures in patients with IE despite the use of AED‟s 
 
 
The minimum duration of an event was 2-3 seconds and the maximum was 5 
minutes excluding status epilepticus with a mean of 2.2 minutes (s.d. 1.5 Minutes) 
and a median of 2 minutes. 
 
46% of patients with intractable epilepsy had provoking factors (21.0% provoked by 
fever, 10.4% Upper respiratory tract infections, 10.4% infection not specified, 2.0% 
pneumonia, 1.0% Urinary tract infections and 1.0% emotional stress).  
 



















Duration taken to recognizing intractability 
Of the IE group only 33.3% (21.9% prior to commencement of the study and 11.4% 
after) were recognised to have intractability, or alternative diagnoses (drug resistant 
epilepsy, refractory epilepsy, severe uncontrolled epilepsy and so on) within the 
medical folders.  The remaining 66.7% were did not have statements in the medical 
records that the children had IE despite most of them being ticked as intractable in 
the stats sheets by their treating doctors!!. 
 
The duration needed to recognize intractability was found to be a median time of 4.8 
years (mean 5.5 years, s.d. 3.6 years). The shortest duration was 7 months and the 
longest was 14.8 years from the onset of seizures. 
 

























In 55% of the patients with IE there was no clear underlying aetiology,  
about 15% had HIE, 9% Infections (3 % hypovolaemic shock  secondary to 
gastroenteritis, 2% encephalitis, 2% meningitis, 1% HIV, 1% sepsis), 7% structural 
brain malformation, 6% head trauma, Dysplastic brain lesions 3% (1% granuloma, 
1% Mesial temporal  and 1% CNS tumours), 2% cerebrovascular event, 2% 
metabolic derangement, 1% genetic. 
 




It is to be noted that we have not included patients with Tuberous Sclerosis (TS) in 
the study as they are all seen in a separate TS clinic that runs weekly. 
In a study conducted in the same centre with the title of “Characteristics of tuberous 
sclerosis complex in a South African cohort” in 2009 it was found that the 
percentage of TS patients using more than two drugs was 18.5% which is very close 










































Associated conditions in patients with intractable epilepsy either an aetiology or not 
are summarized in table 11. 
 
Table 11    Associated conditions and markers 
Condition Number of patients (%) 
Motor disability((Cerebral palsy)) 39 (41.0%) ((29 (30.0%)) 
Perinatal asphyxia markers 
Delivery problems 17 (18.0%) 
Fetal distress 16 (17.0%) 
Postnatal event 12 (12.5%) 
Low apgar score 11 (11.5%) 
Pregnancy problems 8 (8.0%) 
Central nervous system postnatal insults 
Meningitis 5 (5.0%) 
head trauma 6 (6.0%) 
Structural brain lesions or abnormalities 
structural brain malformation 6 (6.0%) 
Birth Microcephaly 5 (5.0%) 
Macrocephaly 4 (4.0%) 
CNS tumour 4 (4.0%) 
Syndromes & complex diseases 
Neurocutaneous disease except TS 9 (9.0%) 
Dysmorphism 9 (9.0%) 
Chromosomal Syndromes 2(2.0%) 
Metabolic disease 2(2.0%) 
Infections (Except CNS infections) 
HIV 4 (4.0%) 
Tuberculosis 9 (9.0%) 
Other Infections 11 (11.0%) 
Other conditions 
Allergies 9 (9.0%) 
Non CNS tumours 3(3.0%) 
Fractures 3(3.0%) 



















As shown in Table 9. Electroencephalogram (EEG), Computed Tomography (CT) 
and Magnetic Resonance Imaging scans were the most frequent investigations 
performed in our patients with intractable epilepsy and even though MRI (50% were 
abnormal, performed in 67%)  was more yielding than CT (40.5% abnormal, 
performed in 87%) it was done less frequently. 
The frequencies of abnormal results detected by the investigations are summarized 
in Table 12. 
 
Table 12    Frequency and Results of investigations performed 
Investigation Frequency (%) Abnormal (%) 
EEG 96 (100.0%) 96 (100.0%) 
Telemetry 9 (9.0%) 6 (6.0%) 
Ultrasound 1 (1.0%) 1 (1.0%) 
CT 84 (87.0%) 34 (34.0%) 
MRI 64 (67.0%) 34 (34.0%) 
SPECT 2 (2.0%) 2 (2.0%) 
 
EEG was performed in all patients with IE and more than once in the majority of 
them. We looked at all available EEG results done near the onset of epilepsy and 
found that Thirty-five (41%) of the abnormal EEG‟s showed focal discharges, 50 
(59%) of the abnormal EEG‟s showed generalized discharges, 27(32%) of the 
abnormal EEG‟s showed non post-ictal and drug related slowing or suppression and 
13 (15%) typical Hypsarythmias. 
 
As shown below, 52 (54%) of the patients had at least three types of investigations 


























Figure 10   Number of different investigations per patient in patients with IE 
 
Management and pharmacological treatment 
Table 13 summarises the number of medications used in both groups. The mean for 
the intractable epilepsy group was 4 drugs, median 4 AEDs, minimum 2 AEDs, 
maximum 7 AEDs (s.d. 1).  
The median for the non-intractable epilepsy group was 1AED, minimum 1 AED, 
maximum 3 AEDs.  
Comparing both groups and running a Chi2 test revealed a p value of <0.05 
indicating a significant difference between both groups as the number of 
medications used is in average about 3-4 times more than that used in the non-
intractable group. 
 
Table.13 Number of drugs administered sorted by intractability 
Number of drugs Intractable  Not Intractable Total 
No. (%) No. (%) No. (%) 
1 0 (0.0%) 351  (84.6%) 351 (68.7%) 
2 21 (21.9%) 62 (14.9%) 83 (16.2%) 
3 26 (27.1%) 4 (1.0%) 30 (5.9%) 
4 22 (22.9%) 0 (0.0%) 22 (4.3%) 
5 14 (14.6%) 0 (0.0%) 14 (2.7%) 
6 11 (11.5%) 0 (0.0%) 11 (2.2%) 

































Figure 11    Number of drugs administered sorted by intractability 
 
Some of the non-intractable group medications exceeded 2 drugs but the 3rd 
medication was considered an adjunctive therapeutic medicine. This was typically 
Clobazam and patient‟s seizures were controlled. 
 
Compliance with medication 
Non-compliance was one of the exclusion criteria and was defined as total non- 
compliance with prescribed medication rather than missing occasional doses.  
As a result 8 patients were excluded from the study. 
 
AEDs used in the patients with IE 
The most frequently used medications when Valproate (67%) and Lamotrigine 
(62%), followed by Carbamazepine (50%) and Clobazam (47%). Medications such 
as phenytoin were rarely used. Other agents were used for specific syndrome 
indications such as Stiripentol in patients with MAE and SMEI and Vigabatrin for a 







































Table 14    Name of medications used by patients with intractable epilepsy 
Name of drug No. of patients Percentage (%) 
Valproate 64 67% 
Lamotrigine 60 62% 
Carbamazepine 48 50% 
Clobazam 45 47% 
Clonazepam 35 37% 
Phenobarbitone 30 31% 
Topiramate 26 27% 
Levetiracetam 16 17% 
Vigabatrin 4 4% 
Stiripentol 2 2% 








Figure 12   Percentage of patient‟s usage of each drug  
 
Appropriateness of trials 
Each medication was reviewed for appropriateness of indication, dosing, 
optimization, frequency and compliance with specific medicine. Confirmation was 
important as they were prerequisite to be enrolled in the study.  
 
Duration of trials of AEDs 























The duration of each medication before consideration of adding another AED or 
discontinuation because of failure was reviewed. The date of the initiation and of 
termination of each drug to calculate the duration was noted. The mean duration 
was 15 months (s.d. 19 month), the minimum was 15 days and that was due to 
occurrence of adverse event, maximum was 6 years and 10 months with a median 
of 11 months.  







Reasons for discontinuation of AEDs  
A total of 331 drug regimes given to our patients with intractable epilepsy were 
reviewed and found that 108 (33%) trials were discontinued. The most common 
reason for discontinuation was unsatisfactory seizure control (57%) followed by 
adverse events (38%) and rarely due to non-availability of the medication (3%), 









































































Other interventions included the use of ACTH, prednisone, pyridoxine or other 
vitamins or elements, ketogenic diet, VNS, epilepsy surgery and others are 
summarized in table15. Ketogenic diet was trialled in 6 patients but only succeeded 
in one (83% of KD trials were unsuccessful to control seizures), 
 
Table 15    Other interventions used among patients with intractable epilepsy 
Intervention No. of patients Percentage 
Prednisone 10 10.4% 
ACTH 6 6.3% 
Pyridoxine 6 6.3% 
Ketogenic diet 6 6.3% 
Biotin 2 2.1% 
Vagal Nerve Stimulation 2 2.1% 
Epilepsy surgery 2 2.1% 
Folinic acid 1 1% 
Intravenous Immunoglobulins 1 1% 
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Complications, co-morbidities and outcome 
Table 16   Aetiology in patients with IE 
Co-morbidity No. of patients Percentage 
Occurrence of Status epilepticus 79 82% 
Developmental problems 65 68% 
Apparent Neuroregression 52 54% 
Behavioural problems 37 38% 
Intellectual disability 35 36% 
Speech delay 16 17% 
Visual problems 16 17% 
Learning difficulties 15 16% 
Microcephaly after onset of Epilepsy 14 15% 
Social problems 13 13.5% 
Motor disability after epilepsy onset 8 8% 
Bulbar dysfunction 7 7% 
Pervasive developmental disorder 8 8% 
Hearing impairment 6 6% 
Gastro-oesophageal reflux disease 5 5% 

































Out of a total of 513 children with epilepsy who attended the outpatient Epilepsy 
services at Red Cross War Memorial Children‟s Hospital in Cape Town, South Africa 
from August 2010 to the end of February 2011, 96 children were identified to meet 
the recent ILAE definition of intractable epilepsy (56). 
The percentage of children with intractable epilepsy using this definition was found 
to be 18.7% which is parallels the prevalence described in the literature of about 
20% (10-25). 
In the Western Cape Province there is an almost equal proportion of male to female 
gender (203). Our cohort reflected this population with a slight but non-significant 
male predominance especially in the intractable epilepsy group (male to female ratio 
1.3:1). Other studies had male predominance (79, 87).   
A higher percentage of patients with IE were of African ancestry and lower 
European when compared to the provincial ancestral distribution (203, 204).        
This discrepancy is likely related to the study being sited in a governmental facility at 
which the proportion of the population services is more directed towards children of 
African and mixed ancestry.  
Most children with IE were between 2 and 12 years of age (mean 7.9 years)at the 
time of the study, only 3.5 % were more than 12 years of age. In the government 
service children over 13 years of age are expected to be referred to the adult 
services. Complex patients undergoing changes in medication are allowed to remain 
in the paediatric service but new referrals over 13 years will be directly referred to 
the adult unit. About 10% of children were not local, this followed the usual referral 
patterns as that the centre is a tertiary referral centre. 
It is well known that epilepsy syndromes are associated with a higher risk of medical 
intractability in children.(178, 205-208)We have found that Epilepsy syndromes that 
were not labelled as benign in the new ILAE classification constituted 57% of our 
patients with IE compared to only 14% in the non-intractable epilepsy group, this is a 
statistically significant finding. Among the IE group the most predominant syndrome 
was Lennox-Gastaut syndrome (27%) followed by epilepsy with myoclonic atonic 
seizures (13.5%), and West syndrome (12.5%). This supports that early recognition 

















Berg et al supported this (49), when other studies were more conflicted, some not 
concurring (77, 87), and others agreeing (58, 79, 80). 
some studies suggested that The age of onset may be a factor in the development 
of IE (19, 21, 69)however studies suggest different stages from the neonatal 
period,(13),the first year of life (209), through into later childhood and 
adolescence(13, 26).. In our group the median age of epilepsy onset was 17.5 
month this reflected the prevalent epilepsy syndrome types which formed our IE 
group.  
Rather than the age of onset, a stronger predictor is the frequency of early seizures 
(11, 13, 19, 21, 22, 24, 48, 49, 60, 66, 67).In our study the onset of seizures 
frequency was consistent with this with a median of 4 per month (mean 58 / month 
(s.d. 108). However this figure was skewed by the children with infantile spasms 
who had as many as 600 seizures per month. 
At the onset only 21% of the group had typical febrile seizures, which were 
considered positive predictors in some studies (24), but not others (11, 79). Other 
seizure types, such as infantile spasms, (15% of our group with IE) are logically 
considered to be predictors of IE (80). 
 
From the IE group of children a median of 12 events per month (mean 60, s.d. 4), 
despite poly-pharmacology, occurred which compares to children with intractable 
epilepsies in several studies worldwide and illustrates the need to revisit the 
management of these children promptly (89).  
 
Only 16% of our patients with intractable epilepsy had family history of epilepsy. 
This was considered in some studies as an independent risk factor of IE (21, 22, 
and 24). 
 
Only 33.3% of our IE group were documented in the medical folders to have 
intractable epilepsy or an alternative equivalent diagnosis (drug resistant epilepsy, 
refractory epilepsy, severe uncontrolled epilepsy and so on). This study has raised 
the awareness of specifically questioning whether the patients managed in the 
Epilepsy service could be intractable. Recognition of this group far earlier in their 
course should increase the chance of identifying these children for aggressive 


















Analyzing the duration taken to recognize intractability found that the median time 
was 4.75 years (Mean 5.5 years, s.d. 3.6 years), these figures were similar to other 
centres worldwide.(63, 64) With more awareness and better application of the 
definition and determination of time needed for each drug trial this figure should 
reduce further. 
 
In 45% of our patients with intractable epilepsy there was an identified underlying 
aetiology. Various aetiologies are important predicting factors of intractability (11, 
21, 22, 49, 72).HIE contributed to 33% of underlying causes, 20% infections, and 
16% structural brain malformation. As such HIE was the leading apparent cause of 
intractability, this is well described in previous studies.(100, 104, 105) In resource 
poor countries more infectious causes were demonstrated when compared to 
developed settings, in our study infectious causes were the seco d leading cause. 
(101) only 2% of these children had HIV and seizures and a direct link to 
intractability could not be demonstrated in this group, contrary to previous 
studies.(210, 211) 
 
As regards risk factors for developing IE, of those patients with HIE, 18% had 
delivery problems, 17% had fetal distress, 11.5% had low Apgar scores and 11% 
postnatal problems. Antenatal pregnancy problems were observed in 8% and 
microcephaly noted at birth in 5%.These findings illustrate the compounding 
challenges of avoidable complications prevalent in resource poor settings leading to 
potential development of IE. . 
 
Although MRI was abnormal in 50% of our children with IE compared to 40% who 
underwent CT, MRI was performed less frequently. Further according to the medical 
records the most frequent explanation was that the patients defaulted their MRI 
bookings. In our setting MRI investigations require special preparations compared to 
CT which is often performed during acute admissions. This is especially the case for 
patients from outside Cape Town. The yield of neuroimaging positive findings 
concur other studies and support that MRI, if available, is a preferred imaging tool to 
CT  when investigating epilepsy patients, especially when surgical intervention is 
considered.(212-215)  
In thirty –two percent  of EEG studies performed early, at the onset of epilepsy, 
among our children with IE there was generalized slowing or suppression recorded,  

















correlation between EEG findings and intractability as suggested in other studies. 
(21, 28, 49) 
Based on the definition which requires the use of at least 3 AEDs, as used by other 
centres, only 14.6% of the total group would be defined as IE compared to the larger 
number identified using the ILAE definition. A reasonable definition accepted 
universally is important for practical as well as research reasons. 
The mean duration of the use of the AEDs before considering agent failure was 
1year and 3months (s.d. 1year and 7 months, median of 11 months) indicating that 
a minimum of 1 year occurred before considering failure of a regimen. This follows 
the ILAE definitions in relation to seizure freedom were it was defined that freedom 
from seizuresfor a minimum of three times the longest preintervention 
interseizureinterval, or 12 months, whichever islonger. Alternatively, treatment 
failureis defined as recurrent seizure(s) after the intervention has been adequately 
applied (56). 
Other non-surgical interventions were used in a very limited number of our patients 
with IE. Some of these interventions did not demonstrate the level of efficacy 
reported elsewhere. The ketogenic diet was used in 6 trials and only 1 succeeded 
(16%) compared to an expected higher success rate in the literature (125,151-153).  
VNS and surgery resulted in variable levels of improvement in IE children‟s seizure 
but this area would need to be studied separately and in more detail to be able to 
comment on the outcome and use. Overall there was a gross under-utilization of 
alternative therapy. This stresses the need to  motivate for access to these 
interventions, based on the service capacity which is typically challenged in 
resource limited settings.  The need to improve resources have already been 
identified and flagged by the developing countriesreport on epilepsy surgery 
(DCRES) (139). 
Although there was a high level of co-morbidities in our children, as described in 
other studies, the  overall the proportion was  lower than that found reported(14, 
174). 15% developed microcephaly after onset of epilepsy. In infants with epilepsy 
this is observed and thought related to negative impact on the maturing brain when 
onset is early,(175)our affected group complied with this having onset at a young 
age. Significant impact with learning difficulties, behavioural problems, visual 
impairment, and bulbar dysfunction in the group with IE indicated how severely the 
children were affected. Early intervention and optimization of seizure control may 















Status epilepticus occurred in 82% of our children with intractable epilepsy and 
several times in each patient which increases the impact of their disease. Admission 
to hospital is inevitable and need for high levels of Phenobarbitone to control the 
status.  
This phenomenon is unavoidable in the IE group and considered a known predictor 
when occurring near the onset of intractability in several studies (11, 21, 22, 48, 49, 
72) 
Even though some of the above co-morbidities or complications may be due to 
underlying aetiologies, further studies are needed to verify how much of these 
problems are related directly to intractability rather than an indirect result of 




















The latest definition of intractable epilepsy by the ILAE provided clear criteria to 
study the prevalence of IE among children with epilepsy at Red Cross Children‟s 
Hospital in Cape Town, South Africa. The prevalence was found to be18.7% among 
children with epilepsy. 
 
When compared to the definitions used by some local experts the prevalence 
dropped by 4.1%, a significant proportion who would have been missed otherwise. 
 
This study identified syndromic epilepsy, onset of epilepsy under 2 years of age, 
high frequency of seizures at the onset of the epilepsy and identification of 
underlying aetiologies were key markers to allow early recognition of intractable 
epilepsy. 
 
It took a mean of 4.7 years to recognize intractability. This period could become 
even shorter as more awareness of the definition is incorporated in routine epilepsy 
management. Directing available resources in a more targeted approach would 
utilise limited resources with most efficacy. 
 
Only a small percentage of our children had access to epilepsy surgery, ketogenic 
diet and vagal nerve stimulator (VNS).  This study confirmed an under-utilisation of 
this reflecting the limited resources even in a tertiary setting. 
 
Several disabilities, specially developmental, intellectual, behavioural and social in 



























Early recognition of IE can be achieved universally if awareness among all 
physicians in the country of the definition of intractability and its predictors 
are raised. 
 
Encouragement and creating channels for early referral of children with 
intractable epilepsy to specialized centres for further intervention and 
management should be possible 
 
Looking at the long lasting and sometimes permanently disabling and 
distressing physical, mental, social and financial outcome and co-morbidities 
associated in children with intractable epilepsy it should be mandatory to 
establish all the basic needs to develop dedicated epilepsy intervention 
programs in South Africa which could provide epilepsy surgery. 
 
More studies are needed in the field of intractable epilepsy in childhood in 
South Africa to further evaluate predictors and outcomes of intractable 
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Intractable epilepsy is failure of adequate trials of two tolerated, appropriately chosen and used 
antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom (Kwan and others, 2009) 
 
 
Seizure freedom is defined as freedom from seizures for a minimum of three times the longest pre intervention inter seizure 











Tick if intractable Epilepsy:  
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Appendix 2 Consent form 
CONSENT  
Dear Carer 
We would like to ask for your permission to include your child in a research study currently on-going in the 
department of neurology at Red Cross Children‟s Hospital.  
The aim of this study is to improve the overall management of all children suffering from severe epilepsy. 
I --------------------------------------- the parent/legal guardian of --------------------------------------- give my consent for the 
records of this child to be used for research regarding the Intractable Epilepsy study in children.  
The doctor has explained to me the study and how it affects my child. I have had the opportunity to ask questions 
relating to the study.  
I also consent for the information to be stored on a confidential database and to be used as part of a published 
article.  
I understand that my child‟s confidentiality will be respected and that this study will not allow another individual to 
recognize my child. 
I understand that I am free to withdraw my child if I wish.  
Geagte Ouers/ Wettige Voog 
Ons wil graag u toestemming hê vir ñ deelname aan n navorsing / studie in Neurlogie Department by die Rooikruis
Kinder Hospitaal, dat u kind deel van die navorsing kan wees.
Die studie sluit in om die behandeling te verbeter van kinders wat aan fits/ aanvalle/ epilepsie ly.
Ek --------------------------------------- naam van ouers / wettige voog --------------------------------------- gee toestemming dat
my king deel van die novorsing studie kan wees.
Die Dokter het my ten volle ingelig oor die aard van die studie, en was ook toegellat om enige vrae te vra – oor die 
navorsing.
Ek as ouer/ voog vertrou dat alle informasie van my kind, hoogstens vertroulik en gerespekteer sal word.
Ek verstaan ook dat indien ek sou besluit om nie my kind tot die studie toe te laat nie, of hom / haar te ontrek sonder
geen probleme.
Mgcini Womntwana Obekekileyo  
Sicela imvume yakho edibanisa umntwana  kwizifundo / ucwaninga  ebhekisa kwicandelo  lezengqondo 
kwisibhedlele sase Red Cross Children‟s Hospital.  
Injongo zezizifundo kukuphuhlisa ulawulo lwabantwana  abaphatheke kakhulu  sisifo sokuwa. 
Mna  --------------------------------------- mzali okanye umgcini wontwana ngokusemthethweni -----------------------------------
---- Ndinika imvume yokuba uphando olumalinga nezifundo zabantwana abanesisifo sokuwa. 
Ugqirha undichazele ngezifundo nendlela ezichaphazela ngayo umntwana wam. 
a. Ndibenalo ithuba lokubuza imibuzo malunga nezifundo.
b. Ndivumelene ukuba ulwazi lugcinwe lubeyimfihlelo,lusetyenziswe njenge nxalenye lenqaku elesasazwayo.
c. Ndiyayiqonda imfihlelo yomntwana wam  ukuba  izakuhlonipheka nokuba ayizuvumelana, nokuba umqaphele
umntwana wakho. 
d. Ndiyayiqonda ukuba ndivumelekile ndimhroxise umntwana wam ukuba ndiyafuna.
Signature \ Hantekening \ Utyikityo: 
Date \ Datum \ Umhla:   \   \ 
Witness \ Getuie \ Ingqina: 

















Appendix 3 Assent form 
 
Assent form  
You are being invited to take part in a study about people with epilepsy. We would like your permission 
to record information about your fits in a database which only the doctors looking after you will be able 
to access. 
If you agree to be part of this study you will not need to do anything in addition to your hospital 
appointments and taking your medicine as usual.   
You do not have to take part in this study and you can change my mind later about being part of the 
study.  
If you decide not to take part in the study it will not affect how you are treated at the hospital in anyway.  
Only my doctors and people who are involved in the study will know you are part of it.  
When the study is finished, the doctors will write a report about what was learned.  










































Appendix 4 Proforma  
Demographics 
Count Number Surname Name DOB Sex Ancestry Local Address 




Semiology Syndromic Local 
Ticked 
Intractable 
Intractability Intractable label 
Date of labeling 
intractability 











Frequency at onset per 
month 









factors Pregnancy risk Delivery fetal distress 
2 1 1 1 Fever 1 1 2 
low apgar birth microcephaly 
Postnatal 
insult 
Meningitis SBM Tumor PM Event 







2 1 2 2 1 Normal 
# Invest. Telemetry tResult EEG eegResult US usResult 
3 0 None 2 xxxxxxxx 0 None 
CT ctResult MRI mriResult SPECT spectResult 
1 Normal 2 xxxxxxxx 0 None 
Neurocutaneous ncType Developmental delay 
Motor 
disability 
mdType PDD pddType 
2 None 1 2 None 2 None 


















2 2 2 2 2 2 2 
GORD Gastrosotmy Social problems 
2 2 2 
Ketogenic diet Effective VNS Surgery Others Type1 Type2 Type3 Type4 




















































2  2  2  1 TB Spine 
NSR Tumor Tumor Type Macrocephaly Other1 Other2 Other3 
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